Emerging Challenge of Type 2 Diabetes: Prospects of Medicinal Plants by Begum, Rokeya et al.
Selection of our books indexed in the Book Citation Index 
in Web of Science™ Core Collection (BKCI)
Interested in publishing with us? 
Contact book.department@intechopen.com
Numbers displayed above are based on latest data collected. 
For more information visit www.intechopen.com
Open access books available
Countries delivered to Contributors from top 500 universities
International  authors and editors
Our authors are among the
most cited scientists
Downloads
We are IntechOpen,
the world’s leading publisher of
Open Access books
Built by scientists, for scientists
12.2%
122,000 135M
TOP 1%154
4,800
20 
Emerging Challenge of Type 2 Diabetes: 
Prospects of Medicinal Plants  
Rokeya Begum1, Mosihuzzaman M2, Azad Khan AK1,2,  
Nilufar Nahar3 and Ali Liaquat1,2 
1Bangladesh Institute of Research and Rehabilitation in Diabetes,  
Endocrine and Metabolic Disorder (BIRDEM);  
2Bangladesh Institute of health sciences (BIHS);  
3Dept of Chemistry, University of Dhaka 
Bangladesh 
1. Introduction 
Diabetes mellitus, a complex metabolic disorder is an increasing concern, worldwide in 
terms of health. The disorder affects more than 100 million people worldwide and by 2030 it 
is predicted to affect 366 million. Type 2 diabetes, the commonest form of the disease 
globally, has now reached epidemic proportions in most parts of the world; rapidly 
developing countries are the forefront of this epidemic  (WHO, 2006). This explosive 
increase in the prevalence of diabetes and the consequences of its complications and 
associated disorders represent the greatest health care challenge the world facing today.  
It has been stated that, in the ‘epidemics’ of diabetes the developing world will suffer the 
most, with a predicted 170% increase in cases that will mainly affect the 45-64 years age 
group; by contrast, the diabetic population in developed countries will increase by only 
40%, and particularly among those aged >65 years (King et. al, 1998). Diabetes is an 
expensive disease, both to manage and because the associated morbidity and premature 
death impact so heavily on work and productivity; the massive increase among people of 
working age in the developing world will put a huge strain on the already overstretched 
health-care resources in these countries. 
Type 2 diabetes is a complex disease. It is characterized by the combination of several 
interacting mechanisms like disturbances in insulin secretion, insulin action, glucose 
production and glucose uptake. Defect in one or more of these mechanisms due to either 
environmental and/or genetic factors, can lead to a dysregulated glucose homeostasis 
depicted by hyperglycemia, the cardinal finding of diabetes. The long-term consequences of 
hyperglycemia are severe including eye, heart, kidney and nerve damage. There is evidence 
that hyperglycemia is the primary cause of microvascular complications i.e retinopathy, 
neuropathy and nephropathy (ADA, 2003). Hyperglycemia also plays a vital role in the 
premature and accelerated development of macrovascular complications such as 
cardiovascular and peripheral vascular diseases. Incidence of coronary heart disease is 
much more common than in non-diabetic people, and up to 75% of patients die from 
cardiovascular causes. Life expectancy for middle-aged patients is shortened by 5-10 years, 
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as compared with the general population (ADA, 2001; Katsilambros et al., 1991; Stamler et 
al., 1993). 
Treatment of Type 2 diabetes is complicated by several factors inherent to the disease 
process. Diet and exercise play very important roles for diabetes management 
(Tuomilehto et al., 2001; Knowler et al., 2002). Oral hypoglycemic agents and/or insulin 
are being used to treat type 2 diabetes, all of which act through one of the pathways 
important in diabetes pathophysiology. However, even with these therapies diabetes 
remains an exceedingly difficult disease to control. No single agent has so far been 
unequivocally accepted to be ‘the drug’ in the management of diabetes. There is, 
therefore, an urgent need to develop new medications or strategies to counter the huge 
increase in cases expected in the future. 
2. Prospects of medicinal plants in the management of type 2 diabetes 
Plants have been used for the treatment of diabetes for centuries. However, their scientific 
evaluation has not constituted a substantial area of front-line pharmacological research in 
diabetes. A limited number of these plant species have been studied and validated for their 
hypoglycemic activities using diabetic animal models and in clinical studies using human 
subjects. Recently interest in plants has been increased particularly due to the relative lack of 
progress in the development of proper and save antidiabetic agents. Better understanding of 
the etipathogenesis of diabetic syndrome has paved the way for a more targeted use of plant 
materials in a modern pharmacological sense. In the perspective of the multiplicity of the 
pharmacological approaches against type 2 diabetes it is evident that plants provide 
interesting possibilities in these area because they contain thousands of compounds of 
which some may be useful as antidiabetic agents by themselves. Morever, the plant 
compound may form the basis for further manipulate to develop proper antidiabetic agents. 
Therefore, search for improved drug(s) against diabetes has remained a major goal among 
the biomedical researchers. Since approach of the scientists for synthesis of the conventional 
drugs has not yet brought expected results, many of them, in recent years, are focusing their 
attention on natural compounds to find, at least a lead if not a compound, of such 
antidiabetic agents. 
2.1 Management of Type 2 diabetes with traditional systems of medicine 
Traditional medicines are a fundamental aspect of basic health care needs globally. Over 
64% of world’s population  (ca. 4.4 bn) use plants, in either crude or extract form as a 
primary health care source (Farnsworth, et al., 1985). A number of plants used as herbal 
drugs for diabetes therapy has been described in Ayurveda, Unani and other indigenous 
systems of medicine. Most of these traditional medicines are prepared from herbs, spices 
and plants, which do not form part of normal diet (Day & Bailey, 1986; Bailey & Day 1989). 
However, several common components of the diet are traditionally recommended for 
regular consumption, and some are additionally taken as infusions, decoctions or alcoholic 
extracts.  
Plant materials have formed the basis for the treatment of diabetes in traditional medicines 
systems for thousands of years. These medicines for the treatment of diabetes mellitus are 
probably based mainly on treatment of its obvious symptoms. In ancient Ayurvedic medical 
texts such as the Charaka Samhita (Ca 2500 B.C.) and Sushruta Samhita (Ca 1000 B.C.) 
www.intechopen.com
 
Emerging Challenge of Type 2 Diabetes: Prospects of Medicinal Plants 
 
377 
glycosuria was recognized as a symptom of diabetes (Nagarajan et al., 1982) whereas 
etiopathogenesis, clinical features and complications of diabetes have been described in 
another Ayurvedic medical text as Rogovinischaya (12thCentury A.D). The Ayurvedic way 
of diabetes management include: advice for active life style, control over diet and different 
formulations for the treatment of diabetic complications. Sixty formulations of herbal and 
herbo-mineral origin under different categories like powder, paste, decoctions, etc. have 
been used in Ayurveda for diabetes management. Many mineral preparations (Bhasma) are 
also recommended. 
2.2 Plant materials and diabetes: Present scenario 
World’s Ethnobotanical information about medicinal plants reports that almost 800 plants 
are used in the control of diabetes mellitus (Ajgaoonkar, 1979, Alarcon- Aguilara et al., 
1998). More than 400 plants world-wide have been documented for the treatment of 
diabetes and majority await proper scientific and medical evaluation (Day & Bailey, 1986). 
Over the last three decades, several comprehensive reviews (Oliver-Bever et al., 1979; 
Bailey, 1989; Ivorra et al., 1989; Subbulakshmi and Naik, 2001; Grover et al., 2002; 
Srinivasa, 2007) and extensive surveys (Marles & Farnsworth, 1995; Simmonds & Howes, 
2006) have been published highlighting the fact that higher plants are of use in the 
treatment of diabetes, providing discussion on botany, phytochemistry, pharmacology 
and, in some cases, toxicology of the botanical agents. The extensive survey by Marles and 
Farnsworth (1995) reported that more than 1200 species of plants (in 725 genera and 183 
families) are in use, and Simmonds and Howes (2006) mentioned that 656 plant species (in 
437 genera and 11 families) have been used to treat diabetes and/or been investigated for 
antidiabetic activity. Recently a database of antidiabetic plants have been published 
(Singh et al., 2007) which contains information of medicinal plants having 
antihyperglycemic or antidiabetic activity. It includes 238 plants species and 123 Indian 
industries, which are using them. 
There are very large and widely distributed families of antidiabetic plants, so the large 
number of species reported to have been used traditionally or experimentally for the 
treatment of diabetes may be coincidental. The most frequently cited families are Fabaceae, 
Asteraceae, Lamiaceae, Liliaceae, Poaceae and Euphorbiaceae (Marles & Farnsworth, 1995). 
The phylogenetic distance between even this select group of families is a strong indication of 
the varied nature of the active constituents.  
2.3 Reported hypoglycemic plant compounds 
Cumulative research over the last few decades have already indicated some promising 
results that plants may serve as a source of antidiabetic compounds (Day, 1995). In many 
instances the chemical constituent(s) in the plant responsible for the biological activity has 
been isolated and identified, and some information is also available concerning the 
mechanism of action. A wide range of plant- derived principles belonging to different 
compounds have demonstrated bioactivity against hyperglycemia (Bailey & Day, 1989; 
Ivorra et al., 1988; Ivorra et al., 1989; Bressler et al., 1969; Day, 1990; Marles & Farnsworth, 
1995). Hypoglycemic Natural Products of different classes are presented in Table 1.  
The wide variety of chemical classes indicate that a variety of mechanisms must be involved in 
the lowering of the blood glucose levels. Some of these compounds may have therapeutic 
potential, while others may produce hypoglycemia, as side effects of their toxicity that is also 
another important concern. 
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Chemical class Number active 
Alkaloids 38 
Carbohydrates 66 
Coumarins  1 
Cyanogenic glycosides  1 
Favonoids  7 
Glycopeptides 20 
Inorganic salts   3 
Iridoids    4 
Lipids   6 
Peptides and amines 15 
Phenolics (simple) 4 
Phenolpropanoid 1 
Steroids 7 
Stilbenes  1 
Sulfur compounds  2 
Terpenoids  17 
Vitamins  2 
Xanthenes  2 
Table 1. Hypoglycemic Natural Products 
2.4 Research work on antidiabetic plant materials done by the Dhaka group 
Collaborative studies between the Biomedical Research group of BIRDEM and the 
Department of Chemistry, University of Dhaka, Bangladesh are conducted on antidiabetic 
plant materials following a standardized approach (Ali et al., 1993). Bangladesh and 
neighboring countries have a rich tradition in indigenous herbal medicine, therefore, in 
search of a new agent, considerable attention has been given on research with antidiabetic 
plant materials. Although screening of plant materials for hypoglycemic activities are 
abundantly found in literature, in-depth studies on the mechanism of action of these 
products are relatively lacking. In this design, a single plant material is tested in three 
models (nondiabetic, Type 1 and Type 2) of rats in three prandial states (fasting, 
simultaneously with oral glucose load, and 30 min before oral glucose load). Analysis of the 
results of these nine series of experiments helps not only to screen the hypoglycemic effects 
of the plant material, but also to postulate on their possible mechanism of action in target 
tissue(s). This, in turn, enables the investigator to conduct further in-depth studies on 
specific target tissue(s). 
During the last twenty years 82 plants from Bangladesh, India, Pakistan, Nepal, Sri-lanka, 
China and Cameroon have been screened following the above approach. Some of them have 
shown promising results. From the results it was evident that screening of plant materials 
for hypoglycemic effects is not a straightforward task. The materials are active in particular 
model(s) and in particular prandial state(s) but may be inactive in other models and other 
prandial states. For example, bulb of a plant Stephania hernandifolia, used as antidiabetic 
remedy by the local people and traditional healers of Eastern Himalayan Belt, India, showed 
significant hyperglycemic activity in nondiabetic rats, no significant activity in Type 2 model 
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rats and significant hypoglycemic activity in Type 1 model rats (Mosihuzzaman et al., 1994). 
The plants which showed promising results on screening, may be summarized into the 
groups as shown in Table 2 on the basis of their probable mechanism of action they have 
been classified into the following groups. 
It is evident that, even the 9 series of experiments, as followed by us, are not fully exhaustive 
as other options are readily conceivable. Moreover, experiments have been done only after 
oral administration. A plant material may well be active when administered through other 
routes. 
 
Possible mechanism of action Name of the plant material 
1. Enhance or promote insulin secretion 
Momordica charantia (Ali et al., 1993) Costus speciosus (Mosihuzzaman et al., 1994) 
Coccinia indica (Nahar et al., 2000 & Rokeya et 
al., 2003) 
Premna integrifolia Linn (Alamgir et al., 2000) 
Spirulina platensis (Rokeya et al., 1999) Bridelia ndellensis (Soheng et al., 2005) 
Nephrolepsis tuberosa (Mosihuzzaman et al., 
1994) 
Swetenia mahagoni (Rokeya et al., 2005) 
Pterospermum semisagittum (Khan et al., 2003)  
2. Inhibition of glucose absorption 
Trigonella foenum graceum (Ali et al., 1995 & 
Hannan et al., 2003) 
Syzgium cumini (Rokeya et al., 1999) 
Plantago ovata (Rokeya et al., 1999)  Musa paradisiaca (Rokeya et al., 2000) 
Allium cepa (Rokeya et al., 1999) Pterospermum acerifolium (Mamun et al., 2001) 
Allium sativum (Rokeya et al., 1999 & Retal et 
al., 1999 & 2000) 
Costus Specious (Mosihuzzaman et al., 1994)  
Allium Wallicha Spirulina platensis (Rokeya et al., 1999) 
Asparagus racemosus (Hannan et al., 2007) Crateava Religiosa
Ocimum sanctum (Alamgir et al., 2000) Mangifera indica (Bhowmik et al., 2009) 
Ipomoea aquatica (Sokeng et al., 2007) Tamarindus indicus
3. Action on the peripheral tissues 
Coccinia indica (Nahar et al., 2000) 
Nephrolepsis tuberosa (Mosihuzzaman et al., 
1994) 
Costus speciosus (Mosihuzzaman et al., 1994)  
4. Mixed activity 
Hemidesmus indicus (Murshed et al., 2005) Gymnema sylvestre (Rokeya et al., 2000) 
Caesalpinia bonducella (Chakrabarti et al., 
2003) 
Ocimum sanctum (Alamgir et al., 2001) 
Allium sativum (Rokeya et al., 2000)  
5. Prevention of islet damage or possibility of ǃ-cell regeneration 
Gymnema sylvestre (Rokeya et al., 1999) 
Stephania hernandifolia (Mosihuzzaman et al., 
1994) 
6.     Improving insulin sensitivity 
        Gymnema sylvestre (Ali et al., 2005)  
Table 2. Anidiabetic plant materials reported by the Dhaka Group 
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2.4.1 Studies on the antidiabetic effect and mechanism of action of Nyctanthes 
Arbortristis Linn. 
This is one example of screening methodology followed by mechanistic study. Nyctanthes 
arbortristis Linn (Seoli) is a shrub (a C3 plant; Rao & Kodandaramaiah, 1982) cultivated as a 
garden plant throughout Bangladesh and in the Sub-Himalayan region. In Ayurvedic and 
Unani medicine the leaves of this plant is used extensively for the treatment of various 
ailments (Singh et al., 1995; Chopra et al., 1956; Srivastava et al., 1990). In Ayurvedic system 
of medicine the seeds are being used for throat and eye diseases, skin infections, intestinal 
worm infection, leprosy, etc (RB Singh & Jindal, 1985). To the best of our knowledge there is 
no published report on the antidiabetic properties of this plant. As a routine screening 
programme this plant has been undertaken for studying the effect on serum glucose level of 
nondiabetic and diabetic rat models. Ripe seeds and fresh leaves of N arbortristis were 
collected from Dhaka, Bangladesh. The plant was identified at Bangladesh National 
Herbarium and a voucher specimen (DACB-35121) was deposited.  
2.4.1.1 Materials & methods 
Aquous extract of seed and 2% ethanol extract of leaf were used for the study at a dose of 
1.25 g/kg bw. Male Long-Evans rats bred at BIRDEM Animal House, weighing between 
180-200 gm were used to carry out the experiment. All the experiments were carried out 
following the International Guidelines for handling of laboratory Animals (Derrell, 1966). 
Type 1 and Type 2 diabetes were produced with intraperitoneal injection of Streptozotocin 
using conventional methods and following the procedure standardized in BIRDEM. Acute 
experiments were done in normal, Type 1 and Type 2 diabetic model rats at different 
prandial states. Blood samples were collected by cutting the tail tip under mild ether 
anesthesia. The  glucose levels in the serum samples in duplicate were estimated by GOD-
PAP method (Boehringer Mannheim GMBH).  Statistical analyses were performed by using 
one- way ANOVA. 
2.4.1.2 Results 
Screening result for hypoglycemic activity of aqueous extract of seed and 2% ethanol extract 
of leaf in nondiabetic rats showed no effect in the fasting or postprandial state when fed 
simultaneously with glucose load. Ethanol extract of arbortristis seed significantly (p<0.05) 
opposed the rise of serum glucose at 60min when the extract was fed 30 minutes before 
glucose load in nondiabetic rats (data not shown). 
Aquous seed and leaf extract did not show any hypoglycemic activity in Type 1 rats in 
fasting and 30 minutes before the glucose load state (Table 3). When administered 
simultaneously with glucose, leaf extract showed significant anti-hyperglycemic effect at 
75min (p<0.05).  
Nyctanthes arbortristis seed extract  significantly lowered fasting blood glucose levels in Type 
2 diabetic rats at 120min (p<0.05) and also showed significant anti-hyperglycemic effect at 
75min (p<0.01) when fed simultaneously with glucose (Table 4). 
Aquous extract of seed was effective in lowering serum glucose level of nondiabetic rats 
only in postprandial states when fed 30 min before glucose load indicating more of a 
systemic action. These also include the possibility of inhibition of gastric emptying 
(Lembcke, 1987) and also the involvement of gut hormones (Creutzfeld, 1979). Seed extract 
also showed significant effect in Type 2 rats at the fasting and in postprandial states when 
fed simultaneously with glucose load. This extract might contain some hypoglycemic 
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Group Serum glucose level mmol/l  
Fasting 0 min 60 min 120 min 
Water control   (n = 6) 22.10 ± 2.91 22.02 ± 2.53 20.29  ± 1.33 
Insulin control     (n = 6) 20.33 ± 0.99 3.60  ± .57***  2.35 ± 0.12***  
N arbortristis ripe seed (n = 7) 22.72  ± 2.53 22.37 ± 2.74 21.11  ± 2.49 
N arbortristis leaf    (n = 7) 21.87 ± 2.20  20.92 ± 2.26 22.29 ± 3.02 
Simultaneously with glucose 
load 
0 min 30 min 75 min 
Water   control (n = 6) 22.25  ± 1.86  34.19 ± 1.31 32.03 ± 0.75 
Insulin   control (n = 6) 22.52 ± 0.47 22.10 ± 0.66*** 11.40 ± 1.15*** 
N arbortristis  ripe seed (n = 10) 24.45 ± 1.20 32.50 ± 1.16 27.11 ± 2.30 
N arbortristis  leaf (n = 8) 22.33 ± 0.82 30.56 ± 1.08  25.91 ± 2.79*  
30 min before glucose load  0 min 60 min 105 min 
Water   control (n = 5) 22.16± 4.64 30.35±3.34  26.65±2.82  
Insulin   control (n = 6) 21.38±3.18 9.47± 4.12*** 5.21±1.97 *** 
N. arbortristis  ripe seed  (n = 7) 19.63 ± 3.25 27.68 ± 2.98 24.35 ± 2.77 
N arbortristis  leaf (n = 6) 19.47±6.07  27.32±3.82 27.21± 4.03 
Values are mean ± SE; n = number of rats; *p<0.05, **p<0.01, ***p<0.001 compared to control rat. 
Table 3. Effect of aqueous extract of Nyctanthes arbortristis seeds and 2% ethanol extract of 
leaves on serum glucose levels of Type 1 diabetic models rats in different prandial states. 
 
Group Serum glucose level mmol/l  
Fasting 0 min 60 min 120 min 
Water control (n = 6)  8.48 ± 0.47  8.36 ± 0.33 7.85 ± 0.22   
Glibenclamide control   (n = 6)  8.36 ± 0.25   7.25 ± 0.32*  6.750 ± 0.24 ** 
N arbortristis  seed (n = 7) 7.21 ± 0.18 8.83 ± 0.10 6.99 ± 0.14* 
N arbortristis  leaf (n = 7)  6.90 ± 0.24  7.77 ± 0.08 7.49 ± 0.13  
Simultaneously with glucose load 0 min 30 min 75 min 
Water   control (n = 6) 8.08 ± 0.99  17.06± 0.49 15.89± 0.54 
Glibenclamide control (n=6) 8.28 ± 0.78 19.19± 1.42 16.97± 1.16 
N arbortristis  seed (n = 8) 8.32 ± 0.92 15.43 ± 1.09 9.01 ± 0.05** 
N arbortristis  leaf  (n = 7) 7.12±0.85 15.42± 1.39 16.22 ± 0.96 
30 min before glucose load  0 min 60 min 105 min 
Water control (n = 6) 9.21 ± 0.50 18.57 ± 1.61 17.63 ± 0.95 
Glibenclamide control (n = 7) 8.99 ± 0.47 16.78 ± 1.94 15.03± 1.68 
N arbortristis seed (n = 5) 9.43 ± 0.28 19.50 ± 1.79 19.01± 1.74 
N arbortristis leaf(n = 6) 9.76 ± 0.81 17.64± 1.74 19.36± 1.62 
Values are mean ± SE; n = number of rats; *p<0.05, **p<0.01, ***p<0.001 compared to control rat. 
Table 4. Effect of aqueous extract of Nyctanthes arbortristis seeds and 2% ethanol extract of 
leaves on fasting serum glucose levels of Type 2 diabetic models rats in different prandial 
states.  
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principles, which act probably by stimulation of insulin secretion from ǃ-cells of islets or 
acting either at the gut level or at the peripheral tissues. Analysis of the nature of the action 
of the 2% ethanol extract of leaf in Type 1 model (no effect in fasting state and 30min before 
glucose load, but significant effect when fed simultaneously with glucose load) indicates its 
probable effect at the glycogen synthesis level, since glycogenesis (enhanced by feeding) is 
the predominant mechanism at fed state in contrast to the gluconeogenesis which is 
characteristically activated at fasting state in diabetic animals (Felig & Bergman, 1990).  
The results of the oral acute hypoglycemic effects on normal and Type 2 diabetic rats at 
fasting and postprandial conditions suggested that blood glucose lowering effect of the seed 
extract of N arbortristis is probably due to enhanced insulin-releasing activity.  
2.4.1.3 Studies on the mechanism of insulin secretion 
The effect of the ethanol (PE080) and chloroform (PE081) extracts of seed were also 
evaluated on insulin secretion together with exploration of their mechanism of action 
together with exploration of their mechanism of action in isolated perfused rat pancreas and 
BRIN-BD11 insulin secreting cell (Rokeya et al., 2006). 
Experimental procedure: To study the effects of the extracts on insulin secretion Long-Evans 
rats were anesthetized with sodium pentobarbital solution and the pancreas was isolated 
and perfused through mesenteric and celiac vessels of whole pancreas at 370C according to 
the Method of Giroix et al. (1983). Both the extracts were dissolved at a dose of 0.1mg/ml in 
Krebs-Ringer bicarbonate buffer containing 2.8 mM or 11.1 mM D glucose. The perfusate 
was continuously gassed with a mixture of O2:CO (95:50). After 20 min equilibration period 
the composition of the perfusate was changed every ten min with plant extracts and other 
reagents. The effluent was collected at 1 minute interval from the portal vein. Effluent 
samples were frozen and stored at -200C for insulin assay. 
Clonal BRIN-BD11 cells (McClenaghan et al., 1996) were also used to evaluate the action of 
ethanol and chloroform extracts on insulin secretion. Cell viability was evaluated by 
modified neutral assay (this part of wrk was done in the Diabetes Research Group, 
University of Ulster, UK). 
For perfusion studies and studies with BRIN-BD11 cells insulin was measured by ELISA 
and by radioimmunoassay respectively. Results are presented as meanSD for a given 
number of observations(n). Data from each set of observations were compared using 
unpaired Student’s t-test and Mann-Whitney U test where appropriate (SPSS for Windows). 
One-way ANOVA was performed and comparisons to the control group was made using 
Dunnet’s test to preserve overall error rate of 5%. Differences were considered significant if 
p<0.05.  
Results 
Fig. 1 shows that PE080 stimulated insulin secretion in isolated perfused rat pancreas which 
caused a significant increase in insulin release during 10 minute perfusion with almost a 6-
fold increase above basal level (Insulin, MSD ng/ml; 0.2040.02 basal vs 1.220.12 PE080, 
Peak value; p<0.001). PE081 did not evoke a significant increase on insulin secretion.  
It is establised that studies using insulinotropic antagonists can define the possible 
mechanism of action in enhancing insulin secretion and confirm absence of insulin leakage 
by more lysis of cells. Therefore, in our experiment one such inhibitor utilized was 
diazoxide, an ATP-sensitive K+ chanel opener. Fig 2 shows that diazoxide (300μM) inhibited 
the insulin enhancing effects of PE080 in the perfused panceaes (Insulin MSD, ng/ml; 
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1.220.12 PE080 vs 0.420.05 PE080 + diazoxide; p<0.01) indicating the involvement of the 
extract in the stimulus-secretion coupling pathway at the closure of K+-ATP channels 
(Henquin, 1992). 
 
                            
 
Fig. 1. Effects of PE081 and PE080 on insulin secretion from perfused rat pancreas in basal 
state. Insulin released in presence of PE080 
 
 
Fig. 2. Insulin release in glucose stimulated state and in presence of diazoxide.  
The insulinotropic effects and cellular detrimental effects of PE080 and PE081 with two 
concentrations of each (50 gµ/ml and 100 µg/ml) were evaluated in BRIN-BD11 cell line. It 
was found that, in this cell line (Table 5) PE080 stimulated insulin release in both the 
concentrations (50 and 100 μg/ml) compared to control (5.6 mM glucose).  The Table 5  
shows that the higher concentration did not affect cell viability. PE081 in 100μg/ml 
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concentration stimulated insulin release which was also not associated with a significant 
reduction in cell viability. 
These findings revealed that PE080 and PE081 exert stimulatory effects on insulin secretion 
from the -cells mediated through a physiological insulinotropic pathway. In vivo studies 
also indicate that aquous extract of Nyctanthes arbortristis seeds decreased serum glucose in 
Type 2 diabetic model rats. The identification of active principle(s) from seeds of Nyctanthes 
arbortristis  PE080 and PE081 may provide interesting possibilities against diabetes. 
 
Group Cell viability (%) Insulin (ng/ml) 
5.6 mM glucose 98.585.19 1.450.087 
PE081 (50 g/ml) 96.704.81 1.460.23 
PE081 (100 g/ml 92.023.87** 2.290.41*** 
PE080 (50 g/ml) 96.394.07 2.260.25*** 
PE080  (100 g/ml) 93.305.15 3.360.60*** 
t/p value   
5.6 mM gl vs PE081 (50 g/ml) 0.75/0.465 0.032/0.975 
5.6 mM gl vs PE081 (100 g/ml) 2.86/0.012 7.044/0.001 
5.6 mM gl vs PE080 (50 g/ml) 0.94/0.364 10.39/0.001 
5.6 mM gl vs PE080 (100 g/ml) 2.041/0.061 10.87/0.001 
Table 5. Effects of different concentrations of PE081 and PE080 of on BRIN-BD11 cell 
viability and insulin secretion. 
2.4.2 Studies on the retardation of glucose absorption in the gut 
The retardation of carbohydrate digestion and absorption in the gut is now a potential 
therapeutic approach for the management of diabetes mellitus. The intestinal disaccharidase 
enzymes (ǂ-glucosidase) are involved in the digestion and absorption of carbohydrate and 
inhibition of these enzymes by the agents may slow this process and thus leads to a slower 
and less pronounced rise in postprandial blood glucose levels. It has been confirmed that 
some plant fractions i.e hot water extract extract of T foenumgraecum  P. ovata  and ethanol 
extracts of O sanctum, A  racemosus,  M indica (Bhowmik 2009), T indica  (not published) 
significantly inhibited the absorption of glucose during perfusion of gut with glucose 
solution, a mechanism postulated before through in vivo experiments. T foenumgraecum 
(Hannan,  et.al., 2003 & 2007a)  , P. ovata  (Hannan,  et.al., 2006a) O sanctum (Hannan,  et.al., 
2006b) and A  racemosus, (Hannan,  et.al., 2007b)  increased unabsorbed sucrose content 
throughout gut when administered with sucrose and also inhibitited intestinal 
disaccharidase enzyme activity, which reveals that the retardation of carbohydrate 
absorption is related to the inhibition of gut enzyme activity. However, they did not increase 
GI tract motility (by Barium meal studies) which suggests that inhibition of glucose 
absorption is not related to enhance peristaltic movement of gut. 
2.4.3 Discussion 
It is utmost important to compile information regarding the toxicity of all medicinal 
plants as plant extracts may exert different types of toxicities like hepatic, renal, cardiac, 
hematological and other toxicities through their inherent properties. Therefore, 
antidiabetic plants which show hypo-/antihyperglycemic properties in animal models or 
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in humans should be tested for their possible toxicities. If found to have some degree of 
toxicity, the risks can be weighed against the benefits and decisions can be made 
regarding their continued availability. The plant materials which have been mentioned 
here, a few of them were studied with a longer durationin in  streptozotocin induced 
diabetic model rats  (Chakrabarti et al 2005; Bandara et al 2010) and also inType 2 diabetic 
subjects (Bandara et al 2019). After chronic oral feeding their serum alanine amino 
transferase (ALT) and serum creatinine levels have been determined as a marker of liver 
and kidney toxicities. Chronic consumption of these plant materials did not indicate any 
adverse effect on liver and kidney functions of Type 2 rats or Type 2 patients as serum ALT 
and creatinine levels remained unchanged throughout study period. It should be kept in 
mind that the inherent properties of the plants are not the sole source of plant related 
hepatic, renal, cardiac, hematological or other disorders. There may be some other factors 
like i) plant material and drug interactions, ii)mistakes in dosage and identification and iii) 
presence of adulterants etc. All these issues of concern should be taken into account to 
eliminate toxicity and ensure the safety of  not only the antidiabetic  but all medicinal plant 
products.  
2.4.4 Practical guidelines regarding usefulness 
To study the traditionally used plant materials is not only a scientific but also a social 
responsibility. Whether liked or not a large number of people, particularly in the developing 
countries, are still dependent on plants. It is important to screen their efficacy and it may 
also be helpful if the best timing, dose and the method of administration of these materials 
can be suggested. It is also important to warn people against injudicious dependence on 
plants for the management of diabetes. Although, the modern treatment for diabetes has not 
reached perfection, it has become possible to control the disorder and lead a normal and 
productive life. So, a clinician must be aware that the well-being of the patient is not 
scarified merely due to a psychological preference to use plant materials. If diabetes of a 
patient is not under control after using plant materials, the clinician should not hesitate to 
use the modern drugs against diabetes. 
3. Conclusions 
Prevalence of diabetes mellitus is increasing and it causes substantial morbidity and 
mortality through macro- and microvascular complication, especially in developing 
countries where adequate treatment is often unavailable. Since almost 90% of the people in 
rural areas of developing countries still rely on traditional medicines for their primary 
health care and scientific investigations of traditional medicines have led to the discovery of 
122 compounds obtained from only 94 species of plants  which are used as drugs worldwide 
(Fabricant & Farnsworth, 2001) therefore, the development of new antidiabetic drug(s) from 
traditionally used plants seems to be probable. From the existing evidence it appears that 
plants have got a vast potential to provide source materials for antidiabetic agents. 
However, this potential has remained largely unexplored. A rationally designed 
interdisciplinary research program i.e. involvement of scientists from diverse disciplines of 
biomedical sciences, may also lead to the development of scientifically tested indigenous, 
remedies for diabetes through sustainable and cost-effective use of medicinal plant 
resources.  
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